<DOC>
	<DOCNO>NCT00948272</DOCNO>
	<brief_summary>The purpose study generate data human immunogenicity safety Purified Vero Rabies Vaccine ( VRVg ) support vaccine registration . Primary Objective : - To demonstrate VRVg least immunogenic reference vaccine , Verorab , term seroconversion rate Day 42 primary vaccination series . Secondary Objectives : - To assess clinical safety VRVg vaccination administer pre-exposure vaccination schedule booster 12 month first vaccination subject . - To describe immune response induce VRVg 21 day two vaccination subset randomize subject 14 day last vaccination primary vaccination series .</brief_summary>
	<brief_title>Study Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine Healthy Adults</brief_title>
	<detailed_description>All subject receive three vaccination primary series booster vaccination 12 month first vaccination .</detailed_description>
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 18 60 year day inclusion Provision sign Informed Consent Form Able attend schedule visit comply trial procedure For woman childbearing potential , avoid become pregnant ( use effective method contraception abstinence least 4 week prior vaccination , least 4 week vaccination ) Entitlement national social security Exclusion Criteria : For woman childbearing potential , known pregnancy positive urine pregnancy test Breastfeeding woman Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Chronic illness , stage could interfere trial conduct completion , opinion Investigator Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine 4 week precede first trial vaccination Planned receipt vaccine 4 week follow trial vaccination Known human immunodeficiency virus ( HIV ) , Hepatitis B surface ( HBs ) antigen , Hepatitis C seropositivity Previous vaccination rabies vaccine ( pre postexposure regimen ) Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular ( IM ) vaccination Subject high risk rabies exposure trial period Subjects deprive freedom administrative court order , emergency setting , hospitalize without his/her consent Febrile illness ( temperature ≥38.0°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment . Study site employee involve protocol may direct access trial relate data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Rabies</keyword>
	<keyword>Rabies virus</keyword>
	<keyword>Purified Vero Rabies Vaccine</keyword>
	<keyword>Serum Free</keyword>
</DOC>